PPARγ and agonists against cancer: Rational design of complementation treatments

PPAR Research

Volumn , Issue , 2008, Pages

  Volpert, Olga V ^a   Veliceasa, Dorina ^a   Schulze Hoëpfner, Frank Thilo ^b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CELECOXIB; CIGLITAZONE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; DOCETAXEL; FARGLITAZAR; FLUOROURACIL; GLITAZAR; GW 0072; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; N ACETYLSARCOSYLGLYCYLVALYL DEXTRO ALLOISOLEUCYLTHREONYLNORVALYLISOLEUCYLARGINYLPROLINE ETHYLAMIDE; NC 2100; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROFECOXIB; ROSIGLITAZONE; TESAGLITAZAR; THIOREDOXIN; TRICHOSTATIN A; TROGLITAZONE; TZD 18; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ATHEROSCLEROSIS; CANCER CELL CULTURE; CANCER RESEARCH; CARCINOGENICITY; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLON CANCER; DIABETES MELLITUS; DRUG BINDING; DRUG EFFECT; DRUG POTENTIATION; FLUID RETENTION; GLIOMA; GLOMERULONEPHRITIS; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; NEPHROTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLEIOTROPY; PROSTATE CANCER; REVIEW; SIDE EFFECT; TUMOR CELL; TUMOR PROMOTION; WEIGHT GAIN;

EID: 57449116993     PISSN: 16874757     EISSN: 16874765     Source Type: Journal    
DOI: 10.1155/2008/945275     Document Type: Review

References (113)

1. Wang T., Xu J., Yu X., Yang R., Han Z. C., Peroxisome proliferator-activated receptor γ in malignant diseases Critical Reviews in Oncology/Hematology 2006 58 1 1 14
2. Bruemmer D., Blaschke F., Law R. E., New targets for PPAR γ in the vessel wall: implications for restenosis International Journal of Obesity 2005 29 supplement 1 S26 S30
3. Margeli A., Kouraklis G., Theocharis S., Peroxisome proliferator activated receptor- γ (PPAR- γ) ligands and angiogenesis Angiogenesis 2003 6 3 165 169
4. Panigrahy D., Shen L. Q., Kieran M. W., Kaipainen A., Therapeutic potential of thiazolidinediones as anticancer agents Expert Opinion on Investigational Drugs 2003 12 12 1925 1937
5. Panigrahy D., Huang S., Kieran M. W., Kaipainen A., PPAR γ as a therapeutic target for tumor angiogenesis and metastasis Cancer Biology and Therapy 2005 4 7 687 693
6. Pistrosch F., Herbrig K., Oelschlaegel U., PPAR γ -agonist rosiglitazone increases number and migratory activity of cultured endothelial progenitor cells Atherosclerosis 2005 183 1 163 167
7. Chu K., Lee S.-T., Koo J.-S., Peroxisome proliferator-activated receptor- γ -agonist, rosiglitazone, promotes angiogenesis after focal cerebral ischemia Brain Research 2006 1093 1 208 218
8. Yokoyama Y., Xin B., Shigeto T., Clofibric acid, a peroxisome proliferator-activated receptor α ligand, inhibits growth of human ovarian cancer Molecular Cancer Therapeutics 2007 6 4 1379 1386
9. Bouck N., PEDF: anti-angiogenic guardian of ocular function Trends in Molecular Medicine 2002 8 7 330 334
10. Asahara T., Isner J. M., Endothelial progenitor cells for vascular regeneration Journal of Hematotherapy and Stem Cell Research 2002 11 2 171 178
11. Shim W. S. N., Ho I. A. W., Wong P. E. H., Angiopoietin: a TIE(d) balance in tumor angiogenesis Molecular Cancer Research 2007 5 7 655 665
12. Asano A., Irie Y., Saito M., Isoform-specific regulation of vascular endothelial growth factor (VEGF) family mRNA expression in cultured mouse brown adipocytes Molecular and Cellular Endocrinology 2001 174 1-2 71 76
13. Michalik L., Desvergne B., Dreyer C., Gavillet M., Laurini R. N., Wahli W., PPAR expression and function during vertebrate development International Journal of Developmental Biology 2002 46 1 105 114
14. Xin X., Yang S., Kowalski J., Gerritsen M. E., Peroxisome proliferator-activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo The Journal of Biological Chemistry 1999 274 13 9116 9121
15. Bishop-Bailey D., Hla T., Endothelial cell apoptosis induced by the peroxisome proliferator-activated receptor (PPAR) ligand 15-deoxy- Δ 12, 14 -prostaglandin J 2 The Journal of Biological Chemistry 1999 274 24 17042 17048
16. Murata T., He S., Hangai M., Peroxisome proliferator-activated receptor- γ ligands inhibit choroidal neovascularization Investigative Ophthalmology and Visual Science 2000 41 8 2309 2317
17. Panigrahy D., Singer S., Shen L. Q., PPAR γ ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis Journal of Clinical Investigation 2002 110 7 923 932
18. Miard S., Fajas L., Atypical transcriptional regulators and cofactors of PPAR γ International Journal of Obesity 2005 29 supplement 1 S10 S12
19. Ricote M., Glass C. K., PPARs and molecular mechanisms of transrepression Biochimica et Biophysica Acta 2007 1771 8 926 935
20. Fu M., Zhang J., Lin Y., Early stimulation and late inhibition of peroxisome proliferator-activated receptor γ (PPAR γ) gene expression by transformino growth factor β in human aortic smooth muscle cells: role of early growth-response factor-1 (Egr-1), activator protein 1 (AP1) and Smads Biochemical Journal 2003 370 3 1019 1025
21. Diradourian C., Girard J., Pégorier J.-P., Phosphorylation of PPARs: from molecular characterization to physiological relevance Biochimie 2005 87 1 33 38
22. Genini D., Catapano C. V., Block of nuclear receptor ubiquitination: a mechanism of ligand-dependent control of peroxisome proliferator-activated receptor δ activity The Journal of Biological Chemistry 2007 282 16 11776 11785
23. Ristow M., Müller-Wieland D., Pfeiffer A., Krone W., Kahn C. R., Obesity associated with a mutation in a genetic regulator of adipocyte differentiation The New England Journal of Medicine 1998 339 14 953 959
24. Hosooka T., Noguchi T., Kotani K., Dok1 mediates high-fat diet-induced adipocyte hypertrophy and obesity through modulation of PPAR- γ phosphorylation Nature Medicine 2008 14 2 188 193
25. Arany Z., Foo S.-Y., Ma Y., HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1 α Nature 2008 451 7181 1008 1012
26. Burgermeister E., Seger R., MAPK kinases as nucleo-cytoplasmic shuttles for PPAR γ Cell Cycle 2007 6 13 1539 1548
27. Winn R. A., Van Scoyk M., Hammond M., Antitumorigenic effect of Wnt 7a and Fzd 9 in non-small cell lung cancer cells is mediated through ERK-5-dependent activation of peroxisome proliferator-activated receptor γ The Journal of Biological Chemistry 2006 281 37 26943 26950
28. Blanquart C., Barbier O., Fruchart J. C., Staels B., Glineur C., Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation Journal of Steroid Biochemistry and Molecular Biology 2003 85 2-5 267 273
29. Feige J. N., Auwerx J., Transcriptional coregulators in the control of energy homeostasis Trends in Cell Biology 2007 17 6 292 301
30. Rubenstrunk A., Hanf R., Hum D. W., Fruchart J.-C., Staels B., Safety issues and prospects for future generations of PPAR modulators Biochimica et Biophysica Acta 2007 1771 8 1065 1081
31. Balint B. L., Nagy L., Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases Endocrine, Metabolic & Immune Disorders-Drug Targets 2006 6 1 33 43
32. Collins A. R., Pleiotropic vascular effects of PPAR γ ligands Drug News and Perspectives 2003 16 4 197 204
33. Giaginis C., Margeli A., Theocharis S., Peroxisome proliferator-activated receptor- γ ligands as investigational modulators of angiogenesis Expert Opinion on Investigational Drugs 2007 16 10 1561 1572
34. Goetze S., Eilers F., Bungenstock A., PPAR activators inhibit endothelial cell migration by targeting Akt Biochemical and Biophysical Research Communications 2002 293 5 1431 1437
35. Hsueh W. A., Jackson S., Law R. E., Control of vascular cell proliferation and migration by PPAR- γ: a new approach to the macrovascular complications of diabetes Diabetes Care 2001 24 2 392 397
36. Cho D.-H., Choi Y. J., Jo S. A., Jo I., Nitric oxide production and regulation of endothelial nitric-oxide synthase phosphorylation by prolonged treatment with troglitazone: evidence for involvement of peroxisome proliferator-activated receptor (PPAR) γ -dependent and PPAR γ -independent signaling pathways The Journal of Biological Chemistry 2004 279 4 2499 2506
37. Goetze S., Bungenstock A., Czupalla C., Leptin induces endothelial cell migration through Akt, which is inhibited by PPAR γ -ligands Hypertension 2002 40 5 748 754
38. Teresi R. E., Planchon S. M., Waite K. A., Eng C., Regulation of the PTEN promoter by statins and SREBP Human Molecular Genetics 2008 17 7 919 928
39. Sassa Y., Hata Y., Aiello L. P., Taniguchi Y., Kohno K., Ishibashi T., Bifunctional properties of peroxisome proliferator-activated receptor γ 1 in KDR gene regulation mediated via interaction with both Sp1 and Sp3 Diabetes 2004 53 5 1222 1229
40. Ramirez S. H., Heilman D., Morsey B., Potula R., Haorah J., Persidsky Y., Activation of peroxisome proliferator-activated receptor γ (PPAR γ) suppresses Rho GTPases in human brain microvascular endothelial cells and inhibits adhesion and transendothelial migration of HIV-1 infected monocytes The Journal of Immunology 2008 180 3 1854 1865
41. Ho T.-C., Yang Y.-C., Chen S.-L., Pigment epithelium-derived factor induces THP-1 macrophage apoptosis and necrosis by the induction of the peroxisome proliferator-activated receptor gamma Molecular Immunology 2008 45 4 898 909
42. Ho T.-C., Chen S.-L., Yang Y.-C., Liao C.-L., Cheng H.-C., Tsao Y.-P., PEDF induces p53-mediated apoptosis through PPAR gamma signaling in human umbilical vein endothelial cells Cardiovascular Research 2007 76 2 213 223
43. Yang Y.-C., Tsao Y.-P., Ho T.-C., Choung I.-P., Peroxisome proliferator-activated receptor- γ agonists cause growth arrest and apoptosis in human ovarian carcinoma cell lines International Journal of Gynecological Cancer 2007 17 2 418 425
44. Kim K. Y., Cheon H. G., Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor γ -activated maxi-K channel opening in human umbilical vein endothelial cells The Journal of Biological Chemistry 2006 281 19 13503 13512
45. Billiet L., Furman C., Larigauderie G., Enhanced VDUP-1 gene expression by PPAR γ agonist induces apoptosis in human macrophage Journal of Cellular Physiology 2008 214 1 183 191
46. Verrier E., Wang L., Wadham C., PPAR γ agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway: role of diacylglycerol kinase Circulation Research 2004 94 11 1515 1522
47. Huang H., Campbell S. C., Bedford D. F., Peroxisome proliferator- activated receptor γ ligands improve the antitumor efficacy of thrombospondin peptide ABT510 Molecular Cancer Research 2004 2 10 541 550
48. Sorrentino S. A., Bahlmann F. H., Besler C., Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor- γ agonist rosiglitazone Circulation 2007 116 2 163 173
49. Redondo S., Hristov M., Gümbel D., Tejerina T., Weber C., Biphasic effect of pioglitazone on isolated human endothelial progenitor cells: involvement of peroxisome proliferator-activated receptor- γ and transforming growth factor- β 1 Thrombosis and Haemostasis 2007 97 6 979 987
50. Melero-Martin J. M., Khan Z. A., Picard A., Wu X., Paruchuri S., Bischoff J., In vivo vasculogenic potential of human blood-derived endothelial progenitor cells Blood 2007 109 11 4761 4768
51. Westerweel P. E., den Ouden K., Nguyen T. Q., Goldschmeding R., Joles J. A., Verhaar M. C., Amelioration of anti-Thy1-glomerulonephritis by PPAR- γ agonism without increase of endothelial progenitor cell homing American Journal of Physiology 2008 294 2 F379 F384
52. Al-Shali K. Z., House A. A., Hanley A. J. G., Genetic variation in PPARG encoding peroxisome proliferator-activated receptor γ associated with carotid atherosclerosis Stroke 2004 35 9 2036 2040
53. Mujumdar V. S., Tummalapalli C. M., Aru G. M., Tyagi S. C., Mechanism of constrictive vascular remodeling by homocysteine: role of PPAR American Journal of Physiology 2002 282 5 C1009 C1015
54. Benkirane K., Amiri F., Diep Q. N., El Mabrouk M., Schiffrin E. L., PPAR- γ inhibits ANG II-induced cell growth via SHIP2 and 4E-BP1 American Journal of Physiology 2006 290 1 H390 H397
55. Wakino S., Hayashi K., Kanda T., Peroxisome proliferator-activated receptor γ ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase SHP-2 Circulation Research 2004 95 5 e45 e55
56. Goetze S., Kintscher U., Kim S., Peroxisome proliferator-activated receptor- γ ligands inhibit nuclear but not cytosolic extracellular signal-regulated kinase/mitogen-activated protein kinase-regulated steps in vascular smooth muscle cell migration Journal of Cardiovascular Pharmacology 2001 38 6 909 921
57. Ogawa D., Nomiyama T., Nakamachi T., Activation of peroxisome proliferator-activated receptor γ suppresses telomerase activity in vascular smooth muscle cells Circulation Research 2006 98 7 e50 e59
58. Bruemmer D., Yin F., Liu J., Regulation of the growth arrest and DNA damage-inducible gene 45 (GADD45) by peroxisome proliferator-activated receptor γ in vascular smooth muscle cells Circulation Research 2003 93 4 e38 e47
59. Okura T., Nakamura M., Takata Y., Watanabe S., Kitami Y., Hiwada K., Troglitazone induces apoptosis via the p53 and Gadd45 pathway in vascular smooth muscle cells European Journal of Pharmacology 2000 407 3 227 235
60. Ruiz E., Redondo S., Gordillo-Moscoso A., Tejerina T., Pioglitazone induces apoptosis in human vascular smooth muscle cells from diabetic patients involving the transforming growth factor- β /activin receptor-like kinase-4/5/7/Smad2 signaling pathway Journal of Pharmacology and Experimental Therapeutics 2007 321 2 431 438
61. Lin Y., Zhu X., McIntee F. L., Interferon regulatory factor-1 mediates PPAR γ -induced apoptosis in vascular smooth muscle cells Arteriosclerosis, Thrombosis, and Vascular Biology 2004 24 2 257 263
62. Han J., Hajjar D. P., Tauras J. M., Feng J., Gotto A. M. Jr., Nicholson A. C., Transforming growth factor- β 1 (TGF- β 1) and TGF- β 2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor- γ The Journal of Biological Chemistry 2000 275 2 1241 1246
63. Chinetti G., Griglio S., Antonucci M., Activation of proliferator- activated receptors α and γ induces apoptosis of human monocyte-derived macrophages The Journal of Biological Chemistry 1998 273 40 25573 25580
64. Sasaki M., Jordan P., Welbourne T., Troglitazone, a PPAR- γ activator prevents endothelial cell adhesion molecule expression and lymphocyte adhesion mediated by TNF- α BMC Physiology 2005 5, article 3 1 12
65. Yano M., Matsumura T., Senokuchi T., Statins activate peroxisome proliferator-activated receptor γ through extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase-dependent cyclooxygenase-2 expression in macrophages Circulation Research 2007 100 10 1442 1451
66. Straus D. S., Glass C. K., Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms Trends in Immunology 2007 28 12 551 558
67. Koeffler H. P., Peroxisome proliferator-activated receptor γ and cancers Clinical Cancer Research 2003 9 1 1 9
68. Bush C. R., Havens J. M., Necela B. M., Functional genomic analysis reveals cross-talk between peroxisome proliferator-activated receptor γ and calcium signaling in human colorectal cancer cells The Journal of Biological Chemistry 2007 282 32 23387 23401
69. Zang C., Wächter M., Liu H., Ligands for PPAR γ and RAR cause induction of growth inhibition and apoptosis in human glioblastomas Journal of Neuro-Oncology 2003 65 2 107 118
70. Kim Y., Suh N., Sporn M., Reed J. C., An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis The Journal of Biological Chemistry 2002 277 25 22320 22329
71. Ohama Y., Harada T., Iwabe T., Taniguchi F., Takenaka Y., Terakawa N., Peroxisome proliferator-activated receptor- γ ligand reduced tumor necrosis factor- α -induced interleukin-8 production and growth in endometriotic stromal cells Fertility and Sterility 2008 89 2 311 317
72. Fu Y.-G., Sung J. J. Y., Wu K.-C., Inhibition of gastric cancer cells associated angiogenesis by 15d-prostaglandin J 2 through the downregulation of angiopoietin-1 Cancer Letters 2006 243 2 246 254
73. Grau R., Iñiguez M. A., Fresno M., Inhibition of activator protein 1 activation, vascular endothelial growth factor, and cyclooxygenase-2 expression by 15-deoxy- Δ 12, 14 -prostaglandin J 2 in colon carcinoma cells: evidence for a redox-sensitive peroxisome proliferator-activated receptor- γ -independent mechanism Cancer Research 2004 64 15 5162 5171
74. Biscetti F., Gaetani E., Flex A., Selective activation of peroxisome proliferator-activated receptor (PPAR) α and PPAR γ induces neoangiogenesis through a vascular endothelial growth factor-dependent mechanism Diabetes 2008 57 5 1394 1404
75. Ptak-Belowska A., Pawlik M. W., Krzysiek-Ma̧czka G., Brzozowski T., Pawlik W. W., Transcriptional upregulation of gastrin in response to peroxisome proliferator-activated receptor gamma agonist triggers cell survival pathways Journal of Physiology and Pharmacology 2007 58 4 793 801
76. Jozkowicz A., Dulak J., Piatkowska E., Placha W., Dembinska-Kiec A., Ligands of peroxisome proliferator-activated receptor- γ increase the generation of vascular endothelial growth factor in vascular smooth muscle cells and in macrophages Acta Biochimica Polonica 2000 47 4 1147 1157
77. Yamakawa K., Hosoi M., Koyama H., Peroxisome proliferator-activated receptor- γ agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells Biochemical and Biophysical Research Communications 2000 271 3 571 574
78. Eibl G., Takata Y., Boros L. G., Growth stimulation of COX-2-negative pancreatic cancer by a selective COX-2 inhibitor Cancer Research 2005 65 3 982 990
79. Fauconnet S., Lascombe I., Chabannes E., Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator- activated receptors in bladder cancer cells The Journal of Biological Chemistry 2002 277 26 23534 23543
80. Chintalgattu V., Harris G. S., Akula S. M., Katwa L. C., PPAR- γ agonists induce the expression of VEGF and its receptors in cultured cardiac myofibroblasts Cardiovascular Research 2007 74 1 140 150
81. Lefebvre A.-M., Chen I., Desreumaux P., Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in C57BL/6J- APC M I i n /+ mice Nature Medicine 1998 4 9 1053 1057
82. Sarraf P., Mueller E., Jones D., Differentiation and reversal of malignant changes in colon cancer through PPAR γ Nature Medicine 1998 4 9 1046 1052
83. Tanaka T., Kohno H., Yoshitani S.-I., Ligands for peroxisome proliferator-activated receptors α and γ inhibit chemically induced colitis and formation of aberrant crypt foci in rats Cancer Research 2001 61 6 2424 2428
84. Mueller E., Smith M., Sarraf P., Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer Proceedings of the National Academy of Sciences of the United States of America 2000 97 20 10990 10995
85. Hau P., Kunz-Schughart L., Bogdahn U., Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas - a phase II study Oncology 2007 73 1-2 21 25
86. Kebebew E., Peng M., Reiff E., A phase II trial of rosiglitazone in patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer Surgery 2006 140 6 960 967
87. Fenner M. H., Elstner E., Peroxisome proliferator-activated receptor- γ ligands for the treatment of breast cancer Expert Opinion on Investigational Drugs 2005 14 6 557 568
88. Debrock G., Vanhentenrijk V., Sciot R., Debiec-Rychter M., Oyen R., Van Oosterom A., A phase II trial with rosiglitazone in liposarcoma patients British Journal of Cancer 2003 89 8 1409 1412
89. McCarty M. F., Barroso-Aranda J., Contreras F., PPARgamma agonists can be expected to potentiate the efficacy of metronomic chemotherapy through CD36 up-regulation Medical Hypotheses 2008 70 2 419 423
90. Ooyama A., Oka T., Zhao H.-Y., Yamamoto M., Akiyama S.-I., Fukushima M., Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts Cancer Letters 2008 267 1 26 36
91. Damber J.-E., Vallbo C., Albertsson P., Lennernäs B., Norrby K., The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin Cancer Chemotherapy and Pharmacology 2006 58 3 354 360
92. Bocci G., Francia G., Man S., Lawler J., Kerbel R. S., Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy Proceedings of the National Academy of Sciences of the United States of America 2003 100 22 12917 12922
93. Fulzele S. V., Chatterjee A., Shaik M. S., Jackson T., Ichite N., Singh M., 15-deoxy- Δ 12, 14 -prostaglandin J 2 enhances docetaxel anti-tumor activity against A549 and H460 non-small-cell lung cancer cell lines and xenograft tumors Anti-Cancer Drugs 2007 18 1 65 78
94. Quesada A. J., Nelius T., Yap R., In vivo upregulation of CD95 and CD95L causes synergistic inhibition of angiogenesis by TSP1 peptide and metronomic doxorubicin treatment Cell Death and Differentiation 2005 12 6 649 658
95. Yap R., Veliceasa D., Emmenegger U., Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy Clinical Cancer Research 2005 11 18 6678 6685
96. Watnick R. S., Cheng Y.-N., Rangarajan A., Ince T. A., Weinberg R. A., Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis Cancer Cell 2003 3 3 219 231
97. Liu D.-C., Zang C.-B., Liu H.-Y., Possinger K., Fan S.-G., Elstner E., A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells Acta Pharmacologica Sinica 2004 25 10 1312 1319
98. Egerod F. L., Nielsen H. S., Iversen L., Thorup I., Storgaard T., Oleksiewicz M. B., Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo Biomarkers 2005 10 4 295 309
99. Lipkowitz S., Dennis P. A., PPAR γ agonists follow an unknown TRAIL in lung cancer Cancer Biology and Therapy 2007 6 1 107 109
100. Zou W., Liu X., Yue P., Khuri F. R., Sun S.-Y., PPAR γ ligands enhance TRAIL-induced apoptosis through DR5 upregulation and c-FLIP downregulation in human lung cancer cells Cancer Biology and Therapy 2007 6 1 99 106
101. Ellisen L. W., Growth control under stress: mTOR regulation through the REDD1-TSC pathway Cell Cycle 2005 4 11 1500 1502
102. Cho D.-H., Choi Y. J., Jo S. A., Troglitazone acutely inhibits protein synthesis in endothelial cells via a novel mechanism involving protein phosphatase 2A-dependent p70 S6 kinase inhibition American Journal of Physiology 2006 291 2 C317 C326
103. Stoeltzing O., Meric-Bernstam F., Ellis L. M., Intracellular signaling in tumor and endothelial cells: the expected and, yet again, the unexpected Cancer Cell 2006 10 2 89 91
104. Núñez N. P., Liu H., Meadows G. G., PPAR- γ ligands and amino acid deprivation promote apoptosis of melanoma, prostate, and breast cancer cells Cancer Letters 2006 236 1 133 141
105. McIntyre K. W., Shuster D. J., Gillooly K. M., A highly selective inhibitor of I κ B kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice Arthritis and Rheumatism 2003 48 9 2652 2659
106. Brennan P., O'Neill L. A. J., Inhibition of nuclear factor κ B by direct modification in whole cells - mechanism of action of nordihydroguaiaritic acid, curcumin and thiol modifiers Biochemical Pharmacology 1998 55 7 965 973
107. Sinicrope F. A., Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer Molecular Carcinogenesis 2006 45 6 447 454
108. Fulzele S. V., Shaik M. S., Chatterjee A., Singh M., Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549 Journal of Pharmacy and Pharmacology 2006 58 3 327 336
109. Yamazaki K., Shimizu M., Okuno M., Synergistic effects of RXR α and PPAR γ ligands to inhibit growth in human colon cancer cells - phosphorylated RXR α is a critical target for colon cancer management Gut 2007 56 11 1557 1563
110. Szatmari I., Vámosi G., Brazda P., Peroxisome proliferator- activated receptor γ -regulated ABCG2 expression confers cytoprotection to human dendritic cells The Journal of Biological Chemistry 2006 281 33 23812 23823
111. Cesario R. M., Stone J., Yen W.-C., Bissonnette R. P., Lamph W. W., Differentiation and growth inhibition mediated via the RXR:PPAR γ heterodimer in colon cancer Cancer Letters 2006 240 2 225 233
112. Chang T.-H., Szabo E., Enhanced growth inhibition by combination differentiation therapy with ligands of peroxisome proliferator-activated receptor- γ and inhibitors of histone deacetylase in adenocarcinoma of the lung Clinical Cancer Research 2002 8 4 1206 1212
113. Knouff C., Auwerx J., Peroxisome proliferator-activated receptor- γ calls for activation in moderation: lessons from genetics and pharmacology Endocrine Reviews 2004 25 6 899 918